Key result
Pembrolizumab therapy in a 71-year-old woman with lung cancer led to the rare co-occurrence of sick sinus syndrome and immune checkpoint inhibitor-associated myocarditis, which resolved with steroid therapy.
Case Report (n=1)
No
Sick sinus syndrome can co-occur with immune checkpoint inhibitor-induced myocarditis and may resolve rapidly with prompt pulse steroid therapy and temporary pacing.
Answers are grounded in this paper and cite their sources.
Raises awareness for sick sinus syndrome with pembrolizumab; leaves open the incidence and optimal management of this rare toxicity.
Immune checkpoint inhibitor (ICI)-induced myocarditis is a potentially life-threatening adverse event. We herein report a rare case of sick sinus syndrome (SSS) co-occurring with ICI-associated myocarditis. A 71-year-old woman with lung cancer undergoing pembrolizumab monotherapy was admitted owing to a fever, worsening kidney function, and sinus bradycardia. She was diagnosed with multi-organ immune-related adverse events, including myocarditis. Pulse steroid therapy was initiated immediately under the support of a temporary pacemaker, which resulted in the resolution of SSS in a few days. Biopsy specimens of the endomyocardium showed active myocarditis. Thus, we should be aware that SSS can co-occur with ICI-induced myocarditis.
No takes yet. Share an insight, caveat, or question.
Nishikawa et al. (2022) conducted a case report in Immune checkpoint inhibitor-associated myocarditis and sick sinus syndrome (n=1). Pembrolizumab was evaluated. Pembrolizumab therapy in a 71-year-old woman with lung cancer led to the rare co-occurrence of sick sinus syndrome and immune checkpoint inhibitor-associated myocarditis, which resolved with steroid therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: